Apolipoprotein A-I (ApoA-I) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Apolipoprotein A-I (ApoA-I) - Pipeline Review, H1 2016

Apolipoprotein A-I (ApoA-I) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Apolipoprotein A-I (ApoA-I) - Pipeline Review, H1 2016
Published Jun 28, 2016
55 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Apolipoprotein A-I (ApoA-I) - Pipeline Review, H1 2016, provides in depth analysis on Apolipoprotein A-I (ApoA-I) targeted pipeline therapeutics.

The report provides comprehensive information on the Apolipoprotein A-I (ApoA-I), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein A-I (ApoA-I) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Apolipoprotein A-I (ApoA-I)
- The report reviews Apolipoprotein A-I (ApoA-I) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Apolipoprotein A-I (ApoA-I) targeted therapeutics and enlists all their major and minor projects
- The report assesses Apolipoprotein A-I (ApoA-I) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Apolipoprotein A-I (ApoA-I) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Apolipoprotein A-I (ApoA-I)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by ide

  
Source:
Document ID
GMDHC0138TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Apolipoprotein A-I (ApoA-I) Overview64
  Apolipoprotein A-I (ApoA-I) Products under Development by Stage of Development71
  Apolipoprotein A-I (ApoA-I) Products under Development by Therapy Area81
  Apolipoprotein A-I (ApoA-I) Products under Development by Indication91
Apolipoprotein A-I (ApoA-I) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Apolipoprotein A-I (ApoA-I) Products under Development by Companies122
Apolipoprotein A-I (ApoA-I) Products under Development by Universities/Institutes142
Apolipoprotein A-I (ApoA-I) Therapeutics Assessment167
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action172
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Apolipoprotein A-I (ApoA-I) Companies Involved in Therapeutics Development235
  Arisaph Pharmaceuticals, Inc.231
  Cerenis Therapeutics Holding SA241
  CSL Limited251
  Esperion Therapeutics, Inc.261
  KineMed, Inc.271
Apolipoprotein A-I (ApoA-I) Drug Profiles2810
  4-WF Drug Profile281
  ARI-1778 Drug Profile291
  CER-001 Drug Profile304
  CSL-112 Drug Profile342
  D-4F Drug Profile361
  KM-011 Drug Profile371
Apolipoprotein A-I (ApoA-I) Dormant Projects381
Apolipoprotein A-I (ApoA-I) Discontinued Products391
Apolipoprotein A-I (ApoA-I) Featured News &Press Releases4014
  Jun 02, 2016: Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS)401
  Jan 28, 2016: Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology411
  Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015411
  Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients421
  Jul 15, 2015: Cerenis Therapeutics Announces the Results of the LOCATION Study431
  Nov 18, 2014: CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated441
  Nov 12, 2014: CSL Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque451
  Sep 03, 2014: Cerenis Receives EMA Orphan Drug Designations for CER-001 for the Treatment of ApoA-I and ABCA-1 Deficiencies461
  Jun 02, 2014: Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS471
  Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001481
  Nov 21, 2013: CSL releases positive data for potential new heart attack therapy and announces next phase of clinical development491
  Nov 05, 2012: Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option For Reducing Recurrent Heart Attack Risk, Early CSL Studies Show501
  Mar 15, 2011: Cerenis Initiates Phase II Study Of CER-001 In Acute Coronary Syndrome511
  Jul 26, 2010: Cerenis And Novasep Receive EUR10.7 Million Funding From French Government For Development Of CER-001521
  May 18, 2010: Cerenis Reports Positive Results From Phase I Study Of CER-001 For Treatment Of Cardiovascular Disease531
Appendix542
  Methodology541
  Coverage541
  Secondary Research541
  Primary Research541
  Expert Panel Validation541
  Contact Us541
  Disclaimer551

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Apolipoprotein A-I (ApoA-I) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Apolipoprotein-A-I-ApoA-I-Pipeline-Review-H1-2016-2088-16042>
  
APA:
Global Markets Direct - Market Research. (2016). Apolipoprotein A-I (ApoA-I) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Apolipoprotein-A-I-ApoA-I-Pipeline-Review-H1-2016-2088-16042>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.